Revenue grew 2.6% at constant currency to €3,574m, with adjusted EBITDA up 2.4% and group profit rising 28.7% year-over-year. Biopharma led growth, while refinancing strengthened liquidity and leverage improved. H1 2026 results support full-year guidance.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.